Innogenetics on its Own
Executive SummaryInnogenetics, like many biotech companies, has built a diagnostics business in order to capture short-term revenues. But it got squeezed by industry consolidation and its response is an aggressive and expensive strategy to increase its emphasis on high-margin, novel tests, which it will use to fund conversion to a direct sales and marketing network in major markets.
You may also be interested in...
The amyloid-targeting drug is years behind Biogen/Eisai’s aducanumab, but its subcutaneous administration and the GRADUATE studies’ design could give Roche’s gantenerumab an advantage.
Correvio's atrial fibrillation drug Brinavess will return to a US FDA advisory committee more than a decade after the agency first declined to approve the drug; FDA still has a series of cardiovascular safety concerns related to the drug and is not convinced by data from the European experience.